within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX40_OmacetaxineMepesuccinate;

model OmacetaxineMepesuccinate
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.222222222222222e-06,
    adminDuration = 600,
    adminMass = 1.25 / 1000000,
    adminCount = 1,
    Vd = 0.126,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.148,
    k12 = 3.361111111111111e-06,
    k21 = 3.361111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>OmacetaxineMepesuccinate</td></tr><tr><td>ATC code:</td><td>L01XX40</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1.25</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>126</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Omacetaxine mepesuccinate (also known as homoharringtonine) is an alkaloid antineoplastic agent approved for the treatment of chronic myeloid leukemia (CML) in adults with resistance and/or intolerance to two or more tyrosine kinase inhibitors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with chronic or accelerated phase chronic myeloid leukemia receiving subcutaneous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01XX40 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end OmacetaxineMepesuccinate;
